Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Blood
    March 2026
  1. FELDMAN AL, Dasari S, Rimsza LM, Scott DW, et al
    Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.
    Blood. 2026;147:1199-1214.
    >> Share

  2. ZAMMAR G, Cheah CY
    Pretransplant promise for PD-1 in Hodgkin lymphoma.
    Blood. 2026;147:1015-1017.
    >> Share

  3. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
    A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
    Blood. 2026;147:1058-1069.
    >> Share

  4. CROMBIE JL, Ahmed S, Frigault MJ, Hunter BD, et al
    Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
    Blood. 2026 Mar 3:blood.2025031733. doi: 10.1182/blood.2025031733.
    >> Share

    February 2026
  5. LI X, Liu M, Shi Q, Du ZS, et al
    CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.
    Blood. 2026 Feb 27:blood.2025031156. doi: 10.1182/blood.2025031156.
    >> Share

  6. MARCOUX P, Gava F, Tosolini M, Gravelle P, et al
    Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL.
    Blood. 2026 Feb 26:blood.2025031309. doi: 10.1182/blood.2025031309.
    >> Share

  7. STEWART J, Damania B
    Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.
    Blood. 2026;147:848-862.
    >> Share

  8. DOWLING MR, Cliff ERS, Jeffrey A, Cashion C, et al
    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
    Blood. 2026 Feb 17:blood.2025032307. doi: 10.1182/blood.2025032307.
    >> Share

  9. YENWONGFAI LN, Francischetti IMB
    Follicular lymphoma transformed to classic Hodgkin lymphoma.
    Blood. 2026;147:800.
    >> Share

  10. SORIAL MN, Malpica Castillo LE, Chiattone C, Julia E, et al
    Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.
    Blood. 2026;147:755-767.
    >> Share

  11. DIEFENBACH C, Jegede O, Wang V, Ansell SM, et al
    A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
    Blood. 2026 Feb 9:blood.2025029546. doi: 10.1182/blood.2025029546.
    >> Share

  12. DORANDO HK, Andrews JM, Khatavkar OU, Borcherding N, et al
    Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.
    Blood. 2026 Feb 9:blood.2025029012. doi: 10.1182/blood.2025029012.
    >> Share


  13. Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term stud
    Blood. 2026;147:703.
    >> Share

    January 2026
  14. URANO Y, Satou A
    Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.
    Blood. 2026;147:602.
    >> Share

  15. CHIODIN G, Tatterton DJ, Rock PJ, Del Rio L, et al
    DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.
    Blood. 2026 Jan 20:blood.2025030049. doi: 10.1182/blood.2025030049.
    >> Share

  16. THOMPSON C, Trneny M, Morschhauser F, Salles G, et al
    PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
    Blood. 2026;147:254-265.
    >> Share

  17. FLERLAGE JE, Feraco AM MD, MMSc, Zhou Y, Zheng Y MS, et al
    Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.
    Blood. 2026 Jan 13:blood.2025029535. doi: 10.1182/blood.2025029535.
    >> Share

  18. ARMAND P
    Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.
    Blood. 2026;147:95.
    >> Share

  19. LAURENT C, Bertoni F
    The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.
    Blood. 2026;147:105-114.
    >> Share

  20. ALDERUCCIO JP, Baggio D, Han S, Ghione P, et al
    Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.
    Blood. 2026 Jan 5:blood.2025031455. doi: 10.1182/blood.2025031455.
    >> Share

  21. WIEGAND L, Silva P, Noerenberg D, Christen F, et al
    Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.
    Blood. 2026 Jan 5:blood.2025030489. doi: 10.1182/blood.2025030489.
    >> Share

    December 2025
  22. ABRAMSON JS, Straus DJ, Bartlett NL, Burke JM, et al
    Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.
    Blood. 2025 Dec 29:blood.2025030190. doi: 10.1182/blood.2025030190.
    >> Share

  23. LUAN D, Valid OB, Beyar-Katz O, Tix T, et al
    Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.
    Blood. 2025 Dec 23:blood.2025031476. doi: 10.1182/blood.2025031476.
    >> Share

  24. STALLS JS, Park DC
    Leukemic phase of hepatosplenic T-cell lymphoma.
    Blood. 2025;146:3129.
    >> Share

  25. DESAI SH, Moskowitz AJ, Merryman RW, Shah HR, et al
    PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.
    Blood. 2025 Dec 17:blood.2025030151. doi: 10.1182/blood.2025030151.
    >> Share

    November 2025

  26. Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.
    Blood. 2025;146:2729.
    >> Share

  27. HOSOYA H, Bastidas Torres AN, Fernandez-Pol S, Gubatan JM, et al
    Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.
    Blood. 2025 Nov 25:blood.2025031423. doi: 10.1182/blood.2025031423.
    >> Share

  28. TAYLOR J
    Big cells, bigger BTK resistance in mantle cell lymphoma.
    Blood. 2025;146:2500-2501.
    >> Share

  29. HU S, Tang G
    Mantle cell lymphoma with KMT2A rearrangement.
    Blood. 2025;146:2491.
    >> Share

  30. FOURNIER B, Latour S
    Methylation profiling: unmasking CAEBV's lymphoma connection.
    Blood. 2025;146:2279-2280.
    >> Share

  31. ELSHARAWI I, Selegean S
    Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.
    Blood. 2025;146:2370.
    >> Share

  32. JAWOREK CP, Brockelmann PJ
    Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?
    Blood. 2025 Nov 1:blood.2025029935. doi: 10.1182/blood.2025029935.
    >> Share

    October 2025
  33. SHANMUGAM M
    Starving lymphoma with alpha-KG supplementation.
    Blood. 2025;146:2151-2153.
    >> Share

  34. PANDIRI M, Arber DA
    Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma.
    Blood. 2025;146:2272.
    >> Share

  35. RONCERAY L, Huibers MHW, Reutter K, Abla O, et al
    High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.
    Blood. 2025 Oct 29:blood.2025031086. doi: 10.1182/blood.2025031086.
    >> Share

  36. VAN MEERTEN T, Kersten MJ, Iacoboni G, Hess GR, et al
    Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
    Blood. 2025 Oct 29:blood.2025029734. doi: 10.1182/blood.2025029734.
    >> Share

  37. VARDHANA SA
    Smarter combos, stronger T cells in lymphoma.
    Blood. 2025;146:1742-1744.
    >> Share

  38. ARMAND P
    Introduction to a review series on follicular lymphoma: solved or insoluble problem?
    Blood. 2025;146:1739-1740.
    >> Share

  39. SHI M, Rech KL
    T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
    Blood. 2025;146:1868.
    >> Share

    September 2025
  40. ZUCCA E, Ceriani L, Ciccone G, Di Rocco A, et al
    Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
    Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823.
    >> Share


  41. Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303-2311.
    Blood. 2025;146:1374.
    >> Share

  42. FALCHI L, Sureda A, Leppa S, Vermaat JS, et al
    Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
    Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
    >> Share

  43. HAVRANEK O
    Classic Hodgkin lymphoma: the journey over the destination.
    Blood. 2025;146:1152-1153.
    >> Share

  44. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
    The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
    Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
    >> Share

  45. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
    Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
    Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
    >> Share

    August 2025
  46. SCHERER F
    Cracking the POD24 code in follicular lymphoma.
    Blood. 2025;146:899-900.
    >> Share


  47. Allo-HCT in Hodgkin lymphoma after CPI.
    Blood. 2025;146:1030.
    >> Share

  48. XU P, Zhu Y, Shi ZY, Wang L, et al
    A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
    Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
    >> Share

  49. CASULO C, Sehn LH
    Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
    Blood. 2025 Aug 14:blood.2024026018. doi: 10.1182/blood.2024026018.
    >> Share

  50. QIU L, Thakral B
    Intrasinusoidal pleomorphic mantle cell lymphoma mimicking intravascular large B-cell lymphoma.
    Blood. 2025;146:897.
    >> Share

  51. REJESKI K, Sanz J, Fei T, Nair MS, et al
    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
    Blood. 2025;146:834-846.
    >> Share

  52. SAM J, Leclercq-Cohen G, Gebhardt S, Surowka M, et al
    Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
    Blood. 2025 Aug 1:blood.2025028863. doi: 10.1182/blood.2025028863.
    >> Share

    July 2025
  53. JAAFAR C, Ethiraj P, Qiu Z, Lin AP, et al
    alpha-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development.
    Blood. 2025 Jul 23:blood.2024028069. doi: 10.1182/blood.2024028069.
    >> Share

  54. WANG W, Cai Q, Liu Y, Nie L, et al
    TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
    Blood. 2025 Jul 23:blood.2024026919. doi: 10.1182/blood.2024026919.
    >> Share

  55. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
    Blood. 2025;146:291-303.
    >> Share

  56. ALDERUCCIO JP, Noy A
    The Treatment of Marginal Zone Lymphoma.
    Blood. 2025 Jul 15:blood.2024028269. doi: 10.1182/blood.2024028269.
    >> Share

  57. BROOKS TR, Zabor EC, Bedelu Y, Yang X MD, et al
    Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
    Blood. 2025 Jul 15:blood.2025029117. doi: 10.1182/blood.2025029117.
    >> Share

  58. SCARISBRICK JJ, Quaglino P, Whittaker SJ, Bagot M, et al
    A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
    Blood. 2025 Jul 15:blood.2025029628. doi: 10.1182/blood.2025029628.
    >> Share

  59. KAULEN LD, Martinez-Lage M, Abramson JS, Karschnia P, et al
    Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy.
    Blood. 2025 Jul 15:blood.2025028964. doi: 10.1182/blood.2025028964.
    >> Share

  60. AL JABRI M, Sakhdari A
    A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case.
    Blood. 2025;146:260.
    >> Share

  61. YANG H, Zhang W, Ravanmehr V, Cui G, et al
    Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
    Blood. 2025;146:191-205.
    >> Share

  62. PERALES MA, Awan FT, Boumendil A, Patel J, et al
    Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.
    Blood. 2025 Jul 7:blood.2024027197. doi: 10.1182/blood.2024027197.
    >> Share

    June 2025
  63. RAI S, Duns G, Frontzek F, Wong JCH, et al
    Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma.
    Blood. 2025 Jun 20:blood.2025028412. doi: 10.1182/blood.2025028412.
    >> Share

  64. FREEMAN CL, Srinivasan S, Hodkinson B, Deshpande S, et al
    Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
    Blood. 2025;145:3052-3056.
    >> Share

  65. MULLER F, Schwingen NR, Hagen M, Scholz JK, et al
    Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
    Blood. 2025 Jun 12:blood.2025028375. doi: 10.1182/blood.2025028375.
    >> Share

  66. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    >> Share

  67. CLAUDEL A, Cottereau AS, Bachy E, Itti E, et al
    Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
    Blood. 2025 Jun 11:blood.2024027727. doi: 10.1182/blood.2024027727.
    >> Share

  68. HAWKES EA, Gregory GP
    Burkitt lymphoma: click here to add to CAR-T?
    Blood. 2025;145:2678-2680.
    >> Share

  69. TOOZE R, Klein U
    Exploiting tumor-derived IL-10 activity in lymphoma therapy.
    Blood. 2025;145:2676-2678.
    >> Share

  70. KITAGAWA Y, Jaffe ES
    Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease.
    Blood. 2025;145:2799.
    >> Share

    May 2025
  71. SHAH B, Nejati R
    Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma.
    Blood. 2025;145:2671.
    >> Share

  72. REED HD, Do H, Weller E, Harris MH, et al
    Lymphoid malignancies in patients with Shwachman-Diamond syndrome.
    Blood. 2025;145:2528-2532.
    >> Share

  73. TUMULURU S, Godfrey JK, Cooper A, Yu J, et al
    Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
    Blood. 2025;145:2460-2472.
    >> Share

  74. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    >> Share

  75. PARRY EM, Okosun J
    An Updated Understanding of Follicular Lymphoma Transformation.
    Blood. 2025 May 15:blood.2024026016. doi: 10.1182/blood.2024026016.
    >> Share

  76. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    >> Share

  77. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
    Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
    Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
    >> Share

  78. PIROSA MC, Bruscaggin A, Terzi di Bergamo L, Salehi M, et al
    A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA.
    Blood. 2025 May 13:blood.2024027355. doi: 10.1182/blood.2024027355.
    >> Share


  79. Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299.
    Blood. 2025;145:2231.
    >> Share

  80. DU MQ
    EMZL at various sites: learning from each other.
    Blood. 2025;145:2117-2127.
    >> Share

  81. PARISI X, Medeiros LJ
    When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma.
    Blood. 2025;145:2104.
    >> Share

  82. CHAPUY B, Wood T, Stewart C, Dunford A, et al
    DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.
    Blood. 2025;145:2041-2055.
    >> Share

    April 2025
  83. MARCO-AYALA J, Ortuno FJ
    Appearances deceive: unmasking mantle cell lymphoma with prolymphocytic morphology.
    Blood. 2025;145:1701.
    >> Share

  84. BRODY JD, Jorgensen J, Belada D, Costello R, et al
    Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
    Blood. 2025;145:1621-1631.
    >> Share

  85. STEIDL C
    The immunotherapy real estate of Hodgkin lymphoma.
    Blood. 2025;145:1445-1447.
    >> Share

  86. GOTTSCHLICH A, Grunmeier R, Hoffmann GV, Nandi S, et al
    Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
    Blood. 2025;145:1536-1552.
    >> Share

  87. TOPP MS, Matasar M, Allan JN, Ansell SM, et al
    Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
    Blood. 2025;145:1498-1509.
    >> Share

    March 2025
  88. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    >> Share

  89. ARAUJO-AYALA F, Beguelin W
    Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.
    Blood. 2025 Mar 16:blood.2024026020. doi: 10.1182/blood.2024026020.
    >> Share

  90. KIM SJ, Lim JQ, Yoon SE, Yang DH, et al
    Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma.
    Blood. 2025 Mar 12:blood.2024027109. doi: 10.1182/blood.2024027109.
    >> Share

  91. PRATS-MARTIN C, Morales-Camacho RM
    Prolymphocytic progression of splenic marginal zone lymphoma.
    Blood. 2025;145:1097.
    >> Share

  92. GONZALEZ MANCERA M, Silva O
    ALK+ anaplastic large cell lymphoma expressing CD33 and myeloid nuclear differentiation antigen.
    Blood. 2025;145:1098.
    >> Share

  93. LI W, Wang R, Wang J, Chai D, et al
    Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
    Blood. 2025;145:1047-1060.
    >> Share

    February 2025
  94. DI M, Maurer MJ, Flowers CR
    End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
    Blood. 2025 Feb 28:blood.2024026978. doi: 10.1182/blood.2024026978.
    >> Share

  95. MULVEY E, Rutherford SC, Leonard JP
    The Future of Follicular Lymphoma Management: Strategies on the Horizon.
    Blood. 2025 Feb 28:blood.2024026017. doi: 10.1182/blood.2024026017.
    >> Share

  96. NGUYEN VTM, Namba H, Porter H, Shlyueva D, et al
    Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma.
    Blood. 2025 Feb 26:blood.2024026534. doi: 10.1182/blood.2024026534.
    >> Share

  97. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    >> Share

  98. ARMAND P
    Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness.
    Blood. 2025;145:653-654.
    >> Share

  99. JAIN P, Wang M
    High-risk MCL: recognition and treatment.
    Blood. 2025;145:683-695.
    >> Share

  100. SILKENSTEDT E, Dreyling M
    Treatment of relapsed/refractory MCL.
    Blood. 2025;145:673-682.
    >> Share

  101. SARKOZY C, Tessoulin B, Chiron D
    Unraveling MCL biology to understand resistance and identify vulnerabilities.
    Blood. 2025;145:696-707.
    >> Share

  102. LEWIS CS, Barraclough A, Hawkes EA
    Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma.
    Blood. 2025 Feb 12:blood.2024025772. doi: 10.1182/blood.2024025772.
    >> Share

  103. CHAVEZ JC, Dickinson M, Munoz J, Ulrickson ML, et al
    Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12).
    Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.
    >> Share

  104. SAMPLES L, Sadrzadeh H, Frigault MJ, Jacobson CA, et al
    Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
    Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831.
    >> Share

  105. KADY N, Abdelrahman S, Rauf AM, Burgess A, et al
    The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.
    Blood. 2025;145:597-611.
    >> Share

  106. GARCIA-LACARTE M, Grijalba SC, Melchor Sanchez J, Pascual M, et al
    IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
    Blood. 2025 Feb 3:blood.2024025755. doi: 10.1182/blood.2024025755.
    >> Share

    January 2025
  107. BACHY E, Linton K
    Frontline treatment of follicular lymphoma: What will it take to change current practice?
    Blood. 2025 Jan 27:blood.2024026019. doi: 10.1182/blood.2024026019.
    >> Share

  108. WANG WJ, Hu Z
    CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements.
    Blood. 2025;145:455.
    >> Share

  109. CABALLERO GONZALEZ AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, et al
    HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
    Blood. 2025 Jan 22:blood.2024026758. doi: 10.1182/blood.2024026758.
    >> Share

  110. ZHOU T, Elenitoba-Johnson KSJ
    HLA-I aberrations in cutaneous T-cell lymphoma.
    Blood. 2025;145:252-253.
    >> Share

  111. YU W, Li P, Zhou L, Yang M, et al
    A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Blood. 2025 Jan 15:blood.2024026401. doi: 10.1182/blood.2024026401.
    >> Share

  112. GOBEL C, Niccolai R, de Groot MHP, Jayachandran J, et al
    Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma.
    Blood. 2025 Jan 10:blood.2024025500. doi: 10.1182/blood.2024025500.
    >> Share

  113. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    >> Share

    December 2024
  114. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    >> Share

  115. YENWONGFAI LN, Francischetti IMB
    Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma.
    Blood. 2024;144:2682.
    >> Share

  116. SEHN LH, Hallek M
    Introduction to a review series on high-risk aggressive lymphoma.
    Blood. 2024;144:2561-2562.
    >> Share

  117. DAVIES AJ
    The high-grade B-cell lymphomas: double hit and more.
    Blood. 2024;144:2583-2592.
    >> Share

  118. ROSCHEWSKI M, Phelan JD, Jaffe ES
    Primary large B-cell lymphomas of immune-privileged sites.
    Blood. 2024;144:2593-2603.
    >> Share

  119. DABROWSKA-IWANICKA A, Nowakowski GS
    DLBCL: who is high risk and how should treatment be optimized?
    Blood. 2024;144:2573-2582.
    >> Share


  120. Flavell JR, Baumforth KRN, Wood VHJ, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 2008;111(1):292-301.
    Blood. 2024;144:2559.
    >> Share

  121. LEE HJ, Ramchandren R, Friedman J, Melear JM, et al
    Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
    Blood. 2024 Dec 2:blood.2024024681. doi: 10.1182/blood.2024024681.
    >> Share

    November 2024
  122. IACOBONI G, Morschhauser F
    Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies.
    Blood. 2024 Nov 14:blood.2024025699. doi: 10.1182/blood.2024025699.
    >> Share

  123. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    >> Share

    October 2024
  124. IQBAL J, Inghirami G, Chan WC
    New insights into the biology of T-cell lymphomas.
    Blood. 2024;144:1873-1886.
    >> Share

  125. DE LEVAL L, Gaulard P, Dogan A
    A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.
    Blood. 2024;144:1855-1872.
    >> Share

  126. MARCHI E, Craig JW, Kalac M
    Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).
    Blood. 2024;144:1898-1909.
    >> Share

  127. MOSKOWITZ AJ, Stuver RN, Horwitz SM
    Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).
    Blood. 2024;144:1887-1897.
    >> Share

  128. SEHN LH, Bartlett NL, Matasar MJ, Schuster SJ, et al
    Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >/=2 prior therapies.
    Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454.
    >> Share

  129. ALDUAIJ W, Jiang A, Villa D, Collinge BJ, et al
    CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL.
    Blood. 2024 Oct 23:blood.2024025725. doi: 10.1182/blood.2024025725.
    >> Share

  130. KUMAR A, Soumerai JD, Abramson JS, Barnes JA, et al
    Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
    Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563.
    >> Share

  131. HU J, Dunbar CE
    T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities.
    Blood. 2024 Oct 11:blood.2024025828. doi: 10.1182/blood.2024025828.
    >> Share

  132. KWANG AC, Duran GE, Fernandez-Pol S, Najidh S, et al
    Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
    Blood. 2024 Oct 10:blood.2024024817. doi: 10.1182/blood.2024024817.
    >> Share

  133. ALIG SK
    FISHing for clarity in double-hit lymphomas.
    Blood. 2024;144:1550-1552.
    >> Share


  134. Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795.
    Blood. 2024;144:1647.
    >> Share

  135. COLLINGE B, Ben-Neriah S, Hilton LK, Alduaij W, et al
    Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.
    Blood. 2024;144:1611-1616.
    >> Share

  136. LAURENT C, Trisal P, Tesson B, Seth S, et al
    Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.
    Blood. 2024 Oct 7:blood.2024024496. doi: 10.1182/blood.2024024496.
    >> Share

  137. WALLACE DS, Loh KP, Casulo C
    How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Blood. 2024 Oct 2:blood.2024024788. doi: 10.1182/blood.2024024788.
    >> Share

    September 2024
  138. POCOCK R, Mansour MR
    T-ALL and T-LBL: a notch apart.
    Blood. 2024;144:1356-1357.
    >> Share

  139. TABATA R, Matsue K
    ALK-positive anaplastic large cell lymphoma, Hodgkin-like pattern with unexplained fever.
    Blood. 2024;144:1460.
    >> Share

  140. QUALLS DA, Armand P, Salles GA
    The current landscape of frontline large B-cell lymphoma trials.
    Blood. 2024 Sep 24:blood.2023023789. doi: 10.1182/blood.2023023789.
    >> Share


  141. Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024;143(12):1080-1090.
    Blood. 2024;144:1349.
    >> Share


  142. Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231-1241.
    Blood. 2024;144:1349.
    >> Share

  143. ABRO B, Maurer MJ, Habermann TM, Burack R, et al
    Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis.
    Blood. 2024 Sep 10:blood.2024025681. doi: 10.1182/blood.2024025681.
    >> Share

  144. MAURER K, Grabski IN, Houot R, Gohil SH, et al
    Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma.
    Blood. 2024 Sep 6:blood.2024024381. doi: 10.1182/blood.2024024381.
    >> Share

    August 2024
  145. ZHOU Q, Chang H
    Circulating composite B- and T-cell lymphoma.
    Blood. 2024;144:1027.
    >> Share

  146. WALLACE DS, Barr PM
    Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
    Blood. 2024;144:800-802.
    >> Share

  147. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
    Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
    Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
    >> Share

  148. PABST T, Bacher U
    Boosting CAR T cells against lymphomas.
    Blood. 2024;144:689-691.
    >> Share

  149. CHANG CA, Emberley E, D'Souza AL, Zhao W, et al
    ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
    Blood. 2024;144:757-770.
    >> Share

  150. WANG T, Silva O
    HHV-8+ diffuse large B-cell lymphoma with EBV coinfection occurring posttransplant.
    Blood. 2024;144:677.
    >> Share

  151. NIE J, Wang C, Zheng L, Liu Y, et al
    Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.
    Blood. 2024 Aug 2:blood.2024024487. doi: 10.1182/blood.2024024487.
    >> Share

  152. KUPPERS R
    MYC translocation architecture in B-NHL.
    Blood. 2024;144:469-471.
    >> Share

  153. ARAFAT S, Don M
    A case of Richter transformation to diffuse large B-cell lymphoma with aberrant T-cell marker expression.
    Blood. 2024;144:586.
    >> Share

    July 2024
  154. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
    Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
    Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
    >> Share

  155. RYAN CE, Cohen JB
    Is rituximab retro in mantle cell lymphoma?
    Blood. 2024;144:241-243.
    >> Share

  156. NABEEL H, Bhagat G
    Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation.
    Blood. 2024;144:339.
    >> Share


  157. Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886.
    Blood. 2024;144:341.
    >> Share

  158. PICCALUGA PP
    SOX11 in EBV-negative Burkitt lymphoma.
    Blood. 2024;144:128-129.
    >> Share

  159. FALINI B, Lazzi S
    Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone.
    Blood. 2024;144:237.
    >> Share

    June 2024
  160. LUCENA LAGE S, Ramaswami R, Rocco J, Rupert A, et al
    Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders.
    Blood. 2024 Jun 28:blood.2024024144. doi: 10.1182/blood.2024024144.
    >> Share

  161. BIDOT S, Feldman AL
    Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2024;143:2808.
    >> Share

  162. FLAIFEL A, Rocco JM
    HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic.
    Blood. 2024;143:2671.
    >> Share

  163. CHRISMAN LP, Trimark PF, Pang Y, Pease DR, et al
    Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify Sezary syndrome patients with low blood burden.
    Blood. 2024 Jun 7:blood.2023023584. doi: 10.1182/blood.2023023584.
    >> Share

    May 2024
  164. SMITH MR, Jegede O, Martin P, Till B, et al
    Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
    Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962.
    >> Share

  165. APAYDIN ARIKAN E, Jaffe ES
    Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces.
    Blood. 2024;143:2337.
    >> Share

  166. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
    CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
    Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
    >> Share

  167. JAIN P, Jelloul FZ
    Biclonal mantle cell lymphoma.
    Blood. 2024;143:2217.
    >> Share

  168. GUPTA M, Bradley J, Massaad E, Burns E, et al
    Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma.
    Blood. 2024 May 22:blood.2024023832. doi: 10.1182/blood.2024023832.
    >> Share

  169. MALINVERNI C, Bernardelli A, Glimelius I, Mirandola M, et al
    Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
    Blood. 2024 May 16:blood.2023023525. doi: 10.1182/blood.2023023525.
    >> Share


  170. MRD and EFS in pediatric T-lymphoblastic lymphoma.
    Blood. 2024;143:2111.
    >> Share


  171. Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
    Blood. 2024;143:2108-2110.
    >> Share

  172. YUAN CT, Ma WL
    Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
    Blood. 2024;143:2106.
    >> Share

  173. RIBERA JM
    MRD: also for T-lymphoblastic lymphoma.
    Blood. 2024;143:2017-2019.
    >> Share

  174. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
    Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
    Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
    >> Share

  175. KIM J, Cho J, Lee MH, Yoon SE, et al
    Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
    Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
    >> Share

  176. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
    T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Blood. 2024;143:1816-1824.
    >> Share

    April 2024
  177. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
    Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
    Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
    >> Share

  178. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
    Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
    >> Share

  179. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
    Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
    Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
    >> Share

  180. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
    Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
    Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
    >> Share

  181. LOCKE FL, Siddiqi T, Jacobson CA, Ghobadi A, et al
    Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
    Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447.
    >> Share

  182. SUREDA-GOMEZ M, Iaccarino I, De Bolos A, Meyer MA, et al
    SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
    Blood. 2024 Apr 15:blood.2023023242. doi: 10.1182/blood.2023023242.
    >> Share

  183. MERLIO JP
    Staphylococcus aureus and Sezary syndrome.
    Blood. 2024;143:1436-1438.
    >> Share

  184. WEI Q, Bueso-Ramos CE
    Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma.
    Blood. 2024;143:1551.
    >> Share

  185. VADIVEL CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, et al
    Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome.
    Blood. 2024;143:1496-1512.
    >> Share

  186. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
    Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
    Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
    >> Share

  187. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  188. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
    Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
    >> Share

    March 2024
  189. GROVER NS, Beaven AW
    T-cell lymphoma: the CAR-T revolution is coming.
    Blood. 2024;143:1201-1202.
    >> Share

  190. GIESSINGER J, Pullarkat ST
    An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis.
    Blood. 2024;143:1315.
    >> Share


  191. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
    Blood. 2024;143:1316.
    >> Share

  192. HILL LC, Rouce RH, Wu MJ, Wang T, et al
    Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
    Blood. 2024;143:1231-1241.
    >> Share

  193. STEIDL C, Stevenson FK
    Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
    Blood. 2024;143:1057-1058.
    >> Share

  194. RYAN CE, Armand P, LaCasce AS
    Frontline Treatment of Mantle Cell Lymphoma.
    Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
    >> Share

  195. GODFREY JK, Gao L, Shouse G, Song JY, et al
    Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
    Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168.
    >> Share

  196. MOLIN D
    Aging Kairos: treating older Hodgkin patients.
    Blood. 2024;143:943-945.
    >> Share

  197. EL HUSSEIN S
    Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression.
    Blood. 2024;143:1055.
    >> Share

  198. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    >> Share

  199. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

    February 2024
  200. SCHUSTER SJ, Huw LY, Bolen CR, Maximov V, et al
    Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Blood. 2024;143:822-832.
    >> Share

  201. FRIEDBERG JW, Bordoni R, Patel-Donnelly D, Larson T, et al
    Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
    Blood. 2024;143:786-795.
    >> Share

  202. OLSZEWSKI AJ
    When B cells rebuff bispecifics.
    Blood. 2024;143:744-746.
    >> Share

  203. LYNCH RC
    Toward a cure for cHL without chemotherapy.
    Blood. 2024;143:741-742.
    >> Share

  204. ANG Z, Thomas-Tikhonenko A
    Lymphoma immunotherapy: the garden of forking paths.
    Blood. 2024;143:655-657.
    >> Share

  205. SCHOOLCRAFT DK, Karrs JX
    Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
    Blood. 2024;143:738.
    >> Share

  206. BOARDMAN AP, Palomba ML
    Does BTKi improve CAR T-cell therapy in MCL?
    Blood. 2024;143:653-655.
    >> Share

  207. TONINO SH, Kersten MJ
    The quest for a cure in follicular lymphoma.
    Blood. 2024;143:475-476.
    >> Share

  208. WINTER JN, Ferreri AJM
    Predicting outcomes in CNS lymphoma with ctDNA.
    Blood. 2024;143:478-480.
    >> Share

  209. HEGER JM, Mattlener J, Schneider J, Godel P, et al
    Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
    Blood. 2024;143:522-534.
    >> Share

  210. CASULO C
    How do you define treatment success in MZL?
    Blood. 2024;143:382-383.
    >> Share

  211. DARNELL EP, Frigault MJ
    Two years later: CD19 CAR-T going the distance.
    Blood. 2024;143:379-380.
    >> Share

  212. GANDHI MK, Kelly GL
    EBNA2: a viral maestra conducting a symphony orchestra.
    Blood. 2024;143:384-385.
    >> Share

    January 2024
  213. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
    SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Blood. 2024 Jan 18:blood.2023022241. doi: 10.1182/blood.2023022241.
    >> Share

  214. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
    SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Blood. 2024;143:1953-1964.
    >> Share

  215. CERCHIETTI L
    Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.
    Blood. 2024 Jan 11:blood.2023021002. doi: 10.1182/blood.2023021002.
    >> Share

  216. COPPO P, Ricard L
    Plasmablastic lymphoma: better refine prognosis.
    Blood. 2024;143:101-102.
    >> Share

  217. DREYLING M, Fowler NH, Dickinson M, Martinez-Lopez J, et al
    Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
    Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567.
    >> Share

  218. RADTKE A, Roschewski M
    The follicular lymphoma tumor microenvironment at single cell and spatial resolution.
    Blood. 2024 Jan 9:blood.2023020999. doi: 10.1182/blood.2023020999.
    >> Share

    December 2023
  219. BARRACLOUGH A, Hawkes EA
    Tribulations of trials in aggressive lymphoma.
    Blood. 2023;142:2232-2234.
    >> Share

  220. VEELKEN H
    Energy overpowers sweet tooth in FL.
    Blood. 2023;142:2226-2229.
    >> Share

  221. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  222. SHEA L, Mehta-Shah N
    Peripheral T-cell lymphoma: Are all patients high-risk?
    Blood. 2023 Dec 24:blood.2023020912. doi: 10.1182/blood.2023020912.
    >> Share

  223. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share

  224. LAURENT C, Dietrich S, Tarte K
    Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
    Blood. 2023 Dec 14:blood.2023021000. doi: 10.1182/blood.2023021000.
    >> Share

  225. SPAARGAREN M
    What's brewing for MALT1 in lymphoma?
    Blood. 2023;142:1939-1941.
    >> Share

  226. LUU BE, Xu SA
    A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
    Blood. 2023;142:2034.
    >> Share

  227. WIMBERGER N, Ober F, Avar G, Grau M, et al
    Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
    Blood. 2023;142:1985-2001.
    >> Share

    November 2023
  228. RAUERT-WUNDERLICH H
    EGR1 changes course in B-cell lymphoma.
    Blood. 2023;142:1850-1851.
    >> Share

  229. CAI J, Lee J
    Cold agglutinin syndrome with unexpected bone marrow CD5+ diffuse large B-cell lymphoma.
    Blood. 2023;142:1935.
    >> Share

  230. ALDERUCCIO JP, Nayak L, Cwynarski K
    How I treat secondary CNS involvement by aggressive lymphomas.
    Blood. 2023;142:1771-1783.
    >> Share

  231. STEVENSON FK PROFESSOR, Forconi F
    The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells.
    Blood. 2023 Nov 22:blood.2023022703. doi: 10.1182/blood.2023022703.
    >> Share

  232. GHESQUIERES H, Krzisch D, Nicolas Virelizier E, Kanoun S, et al
    Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
    Blood. 2023 Nov 18:blood.2023021564. doi: 10.1182/blood.2023021564.
    >> Share

  233. DUELL J, Leipold AM, Appenzeller S, Fuhr V, et al
    Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy.
    Blood. 2023 Nov 17:blood.2023021672. doi: 10.1182/blood.2023021672.
    >> Share

  234. MURAKAMI MA
    Toward rational therapy for mantle cell lymphoma.
    Blood. 2023;142:1504-1506.
    >> Share

  235. ETANCELIN P, Boussaid I
    Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
    Blood. 2023;142:1576.
    >> Share

    October 2023
  236. ABRAMSON JS, Palomba ML, Gordon LI, Lunning MA, et al
    Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
    Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
    >> Share

  237. MINSON AG, Hamad N, Cheah CY, Tam CS, et al
    CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.
    Blood. 2023 Oct 26:blood.2023021306. doi: 10.1182/blood.2023021306.
    >> Share

  238. BROCKELMANN PJ
    AXL-erating mantle cell lymphoma treatment.
    Blood. 2023;142:1411-1412.
    >> Share

  239. GINI G, Tani M, Tucci A, Marcheselli L, et al
    Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
    Blood. 2023;142:1438-1447.
    >> Share

  240. NEELAPU SS, Chavez JC, Sehgal A, Epperla N, et al
    Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5).
    Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243.
    >> Share

  241. COLLINS GP
    Tackling PD1i resistance in Hodgkin lymphoma.
    Blood. 2023;142:1333-1334.
    >> Share

  242. BELADA D, Kopeckova K, Bergua Burgues JM, Stevens D, et al
    Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Blood. 2023;142:1348-1358.
    >> Share

  243. LEOPIZZI M, Mundo L, Messina E, Campolo F, et al
    Epstein-Barr virus encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Blood. 2023 Oct 17:blood.2023021346. doi: 10.1182/blood.2023021346.
    >> Share

  244. DI CIACCIO PR, Polizzotto MN, Cwynarski K, Gerrie AS, et al
    The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.
    Blood. 2023 Oct 13:blood.2023021348. doi: 10.1182/blood.2023021348.
    >> Share

  245. BOMMIER C, Zucca E, Chevret S, Conconi A, et al
    Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.
    Blood. 2023 Oct 6:blood.2023020984. doi: 10.1182/blood.2023020984.
    >> Share

  246. RUSSLER-GERMAIN DA, Cliff ERS, Bartlett NL
    Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.
    Blood. 2023 Oct 5:blood.2023022048. doi: 10.1182/blood.2023022048.
    >> Share


  247. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
    Blood. 2023;142:1255.
    >> Share

  248. MANDATO E, Yan Q, Ouyang J, Paczkowska J, et al
    MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
    Blood. 2023;142:1219-1232.
    >> Share

    September 2023

  249. Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
    Blood. 2023;142:1173-1176.
    >> Share

  250. NARITA K, Takeuchi K
    FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21).
    Blood. 2023;142:1172.
    >> Share

  251. ZHOU N, Busino L
    Targeting epigenetics and ferroptosis in DLBCL.
    Blood. 2023;142:1108-1109.
    >> Share

  252. DIEPSTRA A, Nolte IM, van den Berg A, Magpantay LI, et al
    Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
    Blood. 2023 Sep 25:blood.2023020959. doi: 10.1182/blood.2023020959.
    >> Share

  253. LIU Y, Kimpara S, Hoang NM, Daenthanasanmak A, et al
    EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.
    Blood. 2023 Sep 22:blood.2023020142. doi: 10.1182/blood.2023020142.
    >> Share

  254. QUALLS DA, Lambert N, Caimi PF, Merrill MH, et al
    Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
    Blood. 2023 Sep 22:blood.2023021274. doi: 10.1182/blood.2023021274.
    >> Share

  255. FREEMAN CL, Locke FL
    CARs put age in the rearview mirror.
    Blood. 2023;142:1029-1031.
    >> Share


  256. Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
    Blood. 2023;142:1028.
    >> Share

  257. ZHOU N, Choi J, Grothusen G, Kim BJ, et al
    DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
    Blood. 2023;142:973-988.
    >> Share

  258. HAEBE SE, Day G, Czerwinski DK, Sathe A, et al
    Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
    Blood. 2023 Sep 8:blood.2023020360. doi: 10.1182/blood.2023020360.
    >> Share

  259. CHEAH CY
    Pembrolizumab: a key for some, but not all, HL.
    Blood. 2023;142:861-862.
    >> Share


  260. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2023;142:940.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016